New perspectives on atherogenesis: Role of abnormal triglyceride-rich lipoprotein metabolism

Circulation

Volumn 106, Issue 16, 2002, Pages 2137-2142

  Ginsberg, Henry N ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

Apolipoproteins; Atherosclerosis; Hyperlipoproteinemia; Lipids; Lipoproteins

Indexed keywords

APOLIPOPROTEIN B100; APOLIPOPROTEIN B48; CHYLOMICRON; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ATHEROGENESIS; ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DYSLIPIDEMIA; HYPERTRIGLYCERIDEMIA; LIPOLYSIS; LIPOPROTEIN METABOLISM; PRIORITY JOURNAL; PROTEIN ASSEMBLY; PROTEIN SECRETION; SHORT SURVEY;

CHOLESTEROL, HDL; CORONARY ARTERIOSCLEROSIS; HUMANS; HYPERTRIGLYCERIDEMIA; LIPOPROTEINS; LIPOPROTEINS, LDL; LIVER; TRIGLYCERIDES;

EID: 0037109169     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000035280.64322.31     Document Type: Short Survey

References (78)

1. Ginsberg HN. Hypertriglyceridemia: new insights and new approaches to treatment. Am J Cardiol. 2001;87:1174-1180.
2. Hokanson JE, Austin MA. Plasma triglyceride is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol: a meta-analysis of population-based prospective studies. J Cardiovasc Risk. 1996;3:213-219.
3. Jeppesen J, Hein HO, Suadicani P. et al. Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen Male Study. Circulation. 1998;97:1029-1036.
4. Krauss RM. Triglycerides and atherogenic lipoproteins: rationale for lipid management. Am J Med. 1999;105:58S-62S.
5. Ginsberg HN. Lipoprotein physiology. In: Hoeg J, ed. Endocrinology and Metabolism Clinics of North America. Philadelphia. Pa: WB Saunders Co: 1998:503-519.
6. Shachter NS. Apolipoproteins C-1 and C-III as important modulators of lipoprotein metabolism. Curr Opin Lipidol. 2001;12:297-304.
7. Jong MC, Hofker MH, Havekes LM. Role of ApoCs in lipoprotein metabolism: functional differences between ApoC1, ApoC2, and ApoC3. Arterioscler Thromb Vasc Biol. 1999;19:472-484.
8. Mahley RW, Huang Y, Rall SC. Pathogenesis of type III hyperlipoproteinemia (dysbetalipoproteinemia): questions, quandaries, and paradoxes. J Lipid Res. 1999;40:1933-1949.
9. Alaupovic P, Tavella M, Fesmire J. Separation and identification of apo-B-containing lipoprotein particles in normolipidemic subjects and patients with hyperlipoproteinemias. Adv Exp Med Biol. 1987;210:7-14.
10. Tomiyasu K, Walsh BW, Ikewaki K, et al. Differential metabolism of human VLDL according to content of ApoE and ApoC-III. Arterioscler Thromb Vasc Biol. 2001;21:1494-500.
11. Hussain MM. A proposed model for the assembly of chylomicrons. Atherosclerosis. 2000;148:1-15.
12. Ginsberg HN, Goldberg IJ. Regulation of lipoprotein metabolism. In: Jefferson L, Cherrington A, eds. Handbook of Physiology, vol II. The Endocrine Pancreas and the Regulation of Metabolism. New York, NY: Oxford University Press; 2001. In press.
13. Davis RA. Cell and molecular biology of the assembly and secretion of apolipoprotein B-containing lipoproteins by the liver. Biochim Biophys Acta. 1999;1440:1-31.
14. Berriot-Varoqueaux N, Aggerbeck LP, Samson-Bouma M, et al. The role of the microsomal triglyceride transfer protein in abetalipoproteinemia. Annu Rev Nutr. 2000;20:663-697.
15. Sato R, Miyamoto W, Inoue J, et al. Sterol regulatory element-binding protein negatively regulates microsomal triglyceride transfer protein gene transcription. J Biol Chem. 1999;274:24714-24720.
16. Mensenkamp AR, Jong MC, van Goor H, et al. Apolipoprotein E participates in the regulation of very low density lipoprotein-triglyceride secretion by the liver. J Biol Chem. 1999;274:35711-35718.
17. Huang Y, Ji ZS, Brecht WJ, et al. Overexpression of apolipoprotein E3 in transgenic rabbits causes combined hyperlipidemia by stimulating hepatic VLDL production and impairing VLDL lipolysis. Arterioscler Thromb Vasc Biol. 1999;19:2952-2959.
18. Ginsberg HN, Dixon JL, Goldberg IJ. VLDL cascade system. In: Betteridge DJ, Illingworth R, Shepherd J, eds. Lipoproteins in Health and Disease. London, UK: Arnold Publishers; 1999:55-70.
19. Ginsberg HN, Le N-A, Goldberg IJ, et al. Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI: evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo. J Clin Invest. 1986;78:1287-1295.
20. Maeda N, Li H, Lee D, et al. Targeted disruption of the apolipoprotein C-III gene in mice results in hypotriglyceridemia and protection from postprandial hypertriglyceridemia. J Biol Chem. 1994;269:23610-23616.
21. Merkel M, Kako Y, Radner H, et al. Catalytically inactive lipoprotein lipase expression in muscle of transgenic mice increases very low density lipoprotein uptake: direct evidence that lipoprotein lipase bridging occurs in vivo. Proc Natl Acad Sci U S A. 1998;95:13841-13846.
22. Cooper AD. Hepatic uptake of chylomicron remnants. J Lipid Res. 1997;38:2173-2192.
23. Veniant MM, Zlot CH, Walzem RL, et al. Lipoprotein clearance mechanisms in LDL receptor-deficient "Apo-B48-only" and "Apo-B100-only" mice. J Clin Invest. 1998;102:1559-1568.
24. Mahley RW, Ji ZS. Remnant lipoprotein metabolism: key pathways involving cell-surface heparan sulfate proteoglycans and apolipoprotein E. J Lipid Res. 1999;40:1-16.
25. Connelly PW. The role of hepatic lipase in lipoprotein metabolism. Clin Chim Acta. 1999;286:243-255.
26. Rohlmann A, Gotthardt M, Hammer RE, et al. Inducible inactivation of hepatic LRP gene by cre-mediated recombination confirms role of LRP in clearance of chylomicron remnants. J Clin Invest. 1998;101:689-695.
27. Shelburne F, Hanks J, Meyers W, et al. Effect of apoproteins on hepatic uptake of triglyceride emulsions in the rat. J Clin Invest. 1980;65:652-658.
28. Windler E, Havel RJ. Inhibitory effects of C apolipoproteins from rats and humans on the uptake of triglyceride-rich lipoproteins and their remnants by the perfused rat liver. J Lipid Res. 1985;26:556-565.
29. Kowal RC, Herz J, Weisgraber KH, et al. Apolipoprotein C-I modulates the interaction of apolipoprotein E with beta-migrating very low density lipoproteins (beta-VLDL) and inhibits binding of beta-VLDL to low density lipoprotein receptor-related protein. J Biol Chem. 1990;265:10771-10779.
30. Shachter NS, Ebara T, Ramakrishnan R, et al. Combined hyperlipidemia in transgenic mice overexpressing human apolipoprotein C-I. J Clin Invest. 1996;98:846-855.
31. Reaven GM, Hill DB, Gross RC, et al. Kinetics of triglyceride turnover of very low density lipoproteins of human plasma. J Clin Invest. 1965;44:1826-1833.
32. Ginsberg HN. Lipoprotein physiology in nondiabetic and diabetes states. Diabetes Care. 1991;14:839-855.
33. Sigurdsson G, Nicoll A, Lewis B. Metabolism of very low density lipoproteins in hyperlipidemia: studies of apolipoprotein B kinetics in man. Eur J Clin Invest. 1976;6:167-177.
34. Kissebah AH, Alfarsi S, Adams PW. Integrated regulation of very low density lipoprotein triglyceride and apolipoprotein-B kinetics in man: normolipemic subjects, familial hypertriglyceridemia and familial combined hyperlipidemia. Metabolism. 1981;30:856-868.
35. Chait A, Albers JJ, Brunzell JD. Very low density lipoprotein overproduction in genetic forms of hypertriglyceridaemia. Eur J Clin Invest. 1980;10:17-22.
36. Ginsberg HN. Insulin resistance and cardiovascular disease. J Clin Invest. 2000;106:453-458.
37. Shimomura I, Bashmakov Y, Ikemoto S, et al. Insulin selectively increases SREBP-1c mRNA in the livers of rats with streptozotocin-induced diabetes. Proc Natl Acad Sci U S A. 1999;96:13656-13661.
38. Shimomura I, Hammer RE, Richardson JA, et al. Insulin resistance and diabetes mellitus in transgenic mice expressing nuclear SREBP-1c in adipose tissue: model for congenital generalized lipodystrophy. Genes Dev. 1998;12:3182-3194.
39. Berge KE, Tian H, Graf GA, et al. Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters. Science. 2000;290:1771-1775.
40. Lee MH, Lu K, Hazard S, et al. Identification of a gene, ABCG5, important in the regulation of dietary cholesterol absorption. Nat Genet. 2001;27:79-83.
41. Repa JJ, Mangelsdorf DJ. The role of orphan nuclear receptors in the regulation of cholesterol homeostasis. Annu Rev Cell Dev Biol. 2000;16:459-481.
42. Talmud PJ. Genetic determinants of plasma triglycerides: impact of rare and common mutations. Curr Atheroscler Rep. 2001;3:191-199.
43. Wittrup HH, Nordestgaard BG, Sillesen H, et al. A common mutation in lipoprotein lipase confers a 2-fold increase in risk of ischemic cerebrovascular disease in women but not in men. Circulation. 2000;101:2393-2397.
44. 9 Asn mutation in the lipoprotein lipase gene is associated with increased progression of coronary atherosclerosis. Circulation. 1996;94:1913-1918.
45. Talmud PJ, Bujac S, Hall S, et al. Substitution of asparagine for aspartic acid at residue 9 (D9N) of lipoprotein lipase markedly augments risk of coronary heart disease in male smokers. Atherosclerosis. 2000;149:75-81.
46. Le N-A, Gibson JC, Ginsberg HN. Independent regulation of plasma apolipoproteins CII and CIII concentrations in very low density and high density lipoproteins: implications for the regulation of the catabolism of these lipoproteins. J Lipid Res. 1988;29:669-677.
47. Aalto-Setala K, Fisher EA, Chen X, et al. Mechanism of hypertriglyceridemia in human apolipoprotein (apo) CIII transgenic mice: diminished very low density lipoprotein fractional catabolic rate associated with increased apo CIII and reduced apoE on the particles. J Clin Invest. 1992;90:1889-1900.
48. Ebara T, Ramakrishnan R, Steiner G, et al. Chylomicronemia due to apolipoprotein CIII overexpression in apolipoprotein E-null mice: apolipoprotein CIII-induced hypertriglyceridemia is not mediated by effects on apolipoprotein E. J Clin Invest. 1997;99:2672-268 1.
49. Batal R, Tremblay M, Barrett PH, et al. Plasma kinetics of apoC-III and apoE in normolipidemic and hypertriglyceridemic subjects. J Lipid Res. 2000;41:706-718.
50. Huff MW, Fidge NH, Nestel PJ, et al. Metabolism of C-apolipoproteins: kinetics of C-II, C-III1 and C-III2, and VLDL-apolipoprotein B in normal and hyperlipoproteinemic subjects. J Lipid Res. 1981;22:1235-1246.
51. Malmendier CL, Delcroix C, Lontie JF, et al. Apolipoproteins C-II and C-III metabolism in hypertriglyceridemic patients: effect of a drastic triglyceride reduction by combined diet restriction and fenofibrate administration. Atherosclerosis. 1989;77:139-149.
52. Groenendijk M, Cantor RM, de Bruin TW, et al. The apoAI-CIII-AIV gene cluster. Atherosclerosis. 2001;157:1-11.
53. Talmud PJ, Humphries SE. Apolipoprotein C-III gene variation and dyslipidaemia. Curr Opin Lipidol. 1997;8:154-158.
54. Rees A, Stocks J, Sharpe CR, et al. Deoxyribonucleic acid polymorphism in the apolipoprotein A-1-C-III gene cluster: association with hypertriglyceridemia. J Clin Invest. 1985;76:1090-1095.
55. Dammerman M, Sandkuijl LA, Halaas JL, et al. An apolipoprotein CIII haplotype protective against hypertriglyceridemia is specified by promoter and 3′ untranslated region polymorphisms. Proc Natl Acad Sci U S A. 1993;90:4562-4566.
56. Kliewer SA, Xu HE, Lambert MH, et al. Peroxisome proliferator-activated receptors: from genes to physiology. Recent Prog Horm Res. 2001;56:239-263.
57. Willson TM, Brown PJ, Sternbach DD, et al. The PPARs: from orphan receptors to drug discovery. J Med Chem. 2000;43:527-550.
58. Staels B, Vu-Dac N, Kosykh V, et al. Fibrates down-regulate apolipoprotein C-III expression independent of induction of peroxisomal acyl co-enzyme A oxidase. J Clin Invest. 1995;95:705-712.
59. Hertz R, Bishara-Shieban J, Bar-Tana J. Mode of action of peroxisome proliferators as hypolipidemic drugs: suppression of apolipoprotein C-III. J Biol Chem. 1995;270:13470-13475.
60. Shepherd J, Packard CJ, Stewart JM, et al. Apolipoprotein A and B (Sf 100-400) metabolism during bezafibrate therapy in hypertriglyceridemic subjects. J Clin Invest. 1984;74:2164-2177.
61. Jong MC, Gijbels MJ, Dahlmans VE, et al. Hyperlipidemia and cutaneous abnormalities in transgenic mice overexpressing human apolipoprotein CI. J Clin Invest. 1998;101:145-152.
62. Jong MC, van Ree JH, Dahlmans VE, et al. Reduced very-low-density lipoprotein fractional catabolic rate in apolipoprotein C1-deficient mice. Biochem J. 1997;321(pt 2):445-450.
63. Patsch JR, Miesenbock G, Hopferwieser T, et al. Relation of triglyceride metabolism and coronary artery disease: studies in the postprandial state. Arterioscler Thromb Vasc Biol. 1992;12:1336-1345.
64. Sharrett AR, Patsch W, Sorlie PD, et al. Associations of lipoprotein cholesterols, apolipoproteins A-I and B, and triglycerides with carotid atherosclerosis and coronary heart disease. Arterioscler Thromb Vasc Biol. 1994;14:1098-1104.
65. Ginsberg HN, Jones J, Blaner WS, et al. Association of postprandial triglyceride and retinyl palmitate responses with newly diagnosed exercise-induced myocardial ischemia in middle-aged men and women. Arterioscler Thromb Vasc Biol. 1995;15:1829-1838.
66. Daugherty A, Lange LG, Sobel BE, et al. Aortic accumulation and plasma clearance of beta-VLDL and HDL: effects of diet-induced hypercholesterolemia in rabbits. J Lipid Res. 1985;26:955-963.
67. Proctor SD, Mamo JC. Retention of fluorescent-labelled chylomicron remnants within the intima of the arterial wall: evidence that plaque cholesterol may be derived from postprandial lipoproteins. Eur J Clin Invest. 1998;28:497-503.
68. Rapp JH, Lespine A, Hamilton RL, et al. Triglyceride-rich lipoproteins isolated by selected-affinity anti-apolipoprotein B immunosorption from human atherosclerotic plaque. Arterioscler Thromb Vasc Biol. 1994;14:1767-1774.
69. Babaev VR, Patel MB, Semenkovich CF, et al. Macrophage lipoprotein lipase promotes foam cell formation and atherosclerosis in low density lipoprotein receptor-deficient mice. J Biol Chem. 2000;275:26293-26299.
70. Rutledge JC, Woo MM, Rezai AA, et al. Lipoprotein lipase increases lipoprotein binding to the artery wall and increases endothelial layer permeability by formation of lipolysis products. Circ Res. 1997;80:819-828.
71. Blankenhorn DH, Alaupovic P, Wickham E, et al. Prediction of angiographic change in native human coronary arteries and aortocoronary bypass grafts: lipid and non-lipid factors. Circulation. 1990;81:470-476.
72. Hodis HN, Mack WJ, Azen SP, et al. Triglyceride- and cholesterol-rich lipoproteins have a differential effect on mild/moderate and severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin. Circulation. 1994;90:42-49.
73. Koren E, Corder C, Mueller G, et al. Triglyceride enriched lipoprotein particles correlate with the severity of coronary artery disease. Atherosclerosis. 1996;122:105-115.
74. Sacks FM, Alaupovic P, Moyé LA, et al. VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial. Circulation. 2000;102:1886-1892.
75. Campos H, Moye LA, Glasser SP, et al. Low-density lipoprotein size, pravastatin treatment, and coronary events. JAMA. 2001;286:1468-1474.
76. Miesenbock G, Holzl B, Foger B, et al. Heterozygous lipoprotein lipase deficiency due to a missense mutation as the cause of the triglyceride intolerance with multiple lipoprotein abnormalities. J Clin Invest. 1993;91:448-455.
77. Tall AR, Jiang X-C, Luo Y, et al. George Lyman Duff memorial lecture: lipid transfer proteins, HDL metabolism, and atherogenesis. Arterioscler Thromb Vasc Biol. 2000;1999:20:1185-1188.
78. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med. 1999;341:410-418.